Becker's Healthcare December 2, 2024
Elizabeth Gregerson

With deaths from obesity-related heart disease reportedly increasing by 180% over the past 20 years, more research is being done to learn how GLP-1 medications such as Ozempic, Wegovy, Mounjaro and Zepbound can address outcomes in cardiovascular health.

Here are five recent research findings:

  1. Among patients with Type 2 diabetes, GLP-1 medications reduced major adverse cardiovascular events by 13% when compared to a placebo.
  2. Tirzepatide, the active ingredient in Eli Lilly’s GLP-1 medications Mounjaro and Zepbound, reduced the risk of heart failure by 46% and the risk of both heart failure or cardiovascular death by 38% among individuals with obesity.
  3. Stroke survivors...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Pharma / Biotech
Related Articles:
Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease
A Biologist Explains The ‘Weird’ Habits Of People Who Live To 100+ Years Old
U.S. Health Care Spending Reaches $4.9 Trillion
Medicaid spending on weight loss, diabetes drugs up 500% since 2019: 5 numbers to know
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.

Share This Article